Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Axogen, Inc.AXGN · Entity 4297 | Director | June 09, 2025 | June 11, 2025 |
| Bioventus Inc.BVS · Entity 4996 | Director | June 02, 2026 | June 04, 2026 |
| ELUTIA INC.ELUT · Entity 7342 | Director | June 11, 2026 | June 15, 2026 |
| ENDOLOGIX INC /DE/ELGX · Entity 146591 | Director | April 03, 2019 | April 03, 2019 |
| TELA Bio, Inc.TELA · Entity 7381 | Director | June 09, 2026 | June 11, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Axogen, Inc.
Report date June 09, 2025 · Filed June 11, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 86,743 |
Reported balance
After 2025-06-09 transaction · row 1
1 source rowRow 1 · 2025-06-09 · Sale · Disposed 4,073 · Balance 86,743 F1: The reported price in Column 4 is a weighted average sale price. These shares were sold on June 9, 2025 in multiple transactions at prices ranging from $10.47 to $10.61 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported price in Column 4 is a weighted average sale price. These shares were sold on June 9, 2025 in multiple transactions at prices ranging from $10.47 to $10.61 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units.
Bioventus Inc.
Report date June 02, 2026 · Filed June 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 117,523 |
Reported balance
After 2026-06-02 transaction · row 1
1 source rowRow 1 · 2026-06-02 · Exercise / conversion · Acquired 32,282 · Balance 117,523 |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-06-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-02 · Exercise / conversion · Disposed 32,282 · Balance 0 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F2: The RSUs vested on June 2, 2026. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 25,146 |
Reported balance
After 2026-06-03 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-03 · Grant · Acquired 25,146 · Balance 25,146 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F3: The RSUs shall vest and become exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first Annual Meeting of Stockholders following the date of grant and (ii) the first anniversary of the date of grant, subject to the Reporting Person continuing in service on the Issuer's Board of Directors through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock.
F2: The RSUs vested on June 2, 2026.
F3: The RSUs shall vest and become exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first Annual Meeting of Stockholders following the date of grant and (ii) the first anniversary of the date of grant, subject to the Reporting Person continuing in service on the Issuer's Board of Directors through the applicable vesting date.
ELUTIA INC.
Report date June 11, 2026 · Filed June 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.96 · Expires 2036-06-11 | Direct | 106,393 |
Reported balance
After 2026-06-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-11 · Grant · Acquired 106,393 · Balance 106,393 F1: This option was granted automatically under the Issuer's Non-Employee Director Compensation Program and vests and becomes exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first annual meeting following the date of grant and (ii) the first anniversary of the date of grant, subject to the Reporting Person's continuing in service on the Issuer's board of directors through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted automatically under the Issuer's Non-Employee Director Compensation Program and vests and becomes exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first annual meeting following the date of grant and (ii) the first anniversary of the date of grant, subject to the Reporting Person's continuing in service on the Issuer's board of directors through the applicable vesting date.
ENDOLOGIX INC /DE/
Report date April 03, 2019 · Filed April 03, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 43,200 |
Reported balance
After 2019-04-03 transaction · row 1
1 source rowRow 1 · 2019-04-03 · Purchase · Acquired 22,692 · Balance 43,200 |
TELA Bio, Inc.
Report date June 09, 2026 · Filed June 11, 2026
This filing explicitly reported no securities owned.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ENTELLUS MEDICAL INC
Report date February 28, 2018 · Filed March 01, 2018
Section 16 reporting ended · disclosed 2018-03-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.001 par valueSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-02-28 transaction · row 1
1 source rowRow 1 · 2018-02-28 · Disposition to issuer · Disposed 17,500 · Balance 0 F1: Disposed of pursuant to an Agreement and Plan of Merger, dated December 7, 2017, between Entellus Medical, Inc., Stryker Corporation and Explorer Merger Sub Corp. in exchange for a cash payment of $24.00 per share. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.36 · Expires 2024-12-16 | Direct | 0 |
Reported balance
After 2018-02-28 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-02-28 · Disposition to issuer · Disposed 15,000 · Balance 0 F2: This option, which provided for vesting in quarterly installments over 36 months commencing on December 1, 2014, was canceled in the merger in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $24.00 over the per share exercise price of such option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.26 · Expires 2026-06-14 | Direct | 0 |
Reported balance
After 2018-02-28 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-02-28 · Disposition to issuer · Disposed 10,000 · Balance 0 F3: This option, which provided for vesting in full on the earlier of June 14, 2017 and the date of the annual stockholder meeting following June 14, 2016, was canceled in the merger in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $24.00 over the per share exercise price of such option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.38 · Expires 2027-06-13 | Direct | 0 |
Reported balance
After 2018-02-28 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2018-02-28 · Disposition to issuer · Disposed 5,000 · Balance 0 F4: This option, which provided for vesting in full on the earlier of June 13, 2018 and the date of the annual stockholder meeting following June 13, 2017, was canceled in the merger in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $24.00 over the per share exercise price of such option. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to an Agreement and Plan of Merger, dated December 7, 2017, between Entellus Medical, Inc., Stryker Corporation and Explorer Merger Sub Corp. in exchange for a cash payment of $24.00 per share.
F2: This option, which provided for vesting in quarterly installments over 36 months commencing on December 1, 2014, was canceled in the merger in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $24.00 over the per share exercise price of such option.
F3: This option, which provided for vesting in full on the earlier of June 14, 2017 and the date of the annual stockholder meeting following June 14, 2016, was canceled in the merger in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $24.00 over the per share exercise price of such option.
F4: This option, which provided for vesting in full on the earlier of June 13, 2018 and the date of the annual stockholder meeting following June 13, 2017, was canceled in the merger in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $24.00 over the per share exercise price of such option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 19, 2021 Filed May 21, 2021 20:21 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 15,000 | $5.09 | $76,350.00 |
DisclosureSEC source: 0000805928-21-000096 · wf-form4_162162845853460.xml · nonDerivative · entry 2 NEELS GUIDO J · CIK 0001222362 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,591 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The Reporting Person has elected to exercise and hold the shares at this time. Read SEC document |
| May 19, 2021 Filed May 21, 2021 20:21 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 25,000 | $3.80 | $95,000.00 |
DisclosureSEC source: 0000805928-21-000096 · wf-form4_162162845853460.xml · nonDerivative · entry 1 NEELS GUIDO J · CIK 0001222362 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,591 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The Reporting Person has elected to exercise and hold the shares at this time. Read SEC document |
| May 19, 2021 Filed Jun 7, 2021 21:25 UTC Amendment | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionStock Option (right to purchase) · Derivative | 15,000 | $5.09 Strike: $5.09 | $76,350.00 |
DisclosureSEC source: 0000805928-21-000115 · wf-form4a_162310109457355.xml · derivative · entry 4 NEELS GUIDO J · CIK 0001222362 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2022-12-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: All shares of Common Stock underlying the employee stock option became fully vested on December 31, 2016 (1 year from the option grant date) based upon a vesting schedule whereby 25% of the total shares vested at the end of each fiscal quarter. Read SEC document |
| May 19, 2021 Filed Jun 7, 2021 21:25 UTC Amendment | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionStock Option (right to buy) · Derivative | 25,000 | $3.80 Strike: $3.80 | $95,000.00 |
DisclosureSEC source: 0000805928-21-000115 · wf-form4a_162310109457355.xml · derivative · entry 3 NEELS GUIDO J · CIK 0001222362 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2022-08-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: All shares of Common Stock underlying the employee stock option became fully vested on August 26, 2017 (2 years from the option grant date) based upon a vesting schedule whereby 12.5% of total shares vested at the end of each fiscal quarter. Read SEC document |
| May 19, 2021 Filed Jun 7, 2021 21:25 UTC Amendment | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 15,000 | $5.09 | $76,350.00 |
DisclosureSEC source: 0000805928-21-000115 · wf-form4a_162310109457355.xml · nonDerivative · entry 2 NEELS GUIDO J · CIK 0001222362 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,591 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: The Reporting Person has elected to exercise and hold the shares at this time. Read SEC document |
| May 19, 2021 Filed Jun 7, 2021 21:25 UTC Amendment | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 25,000 | $3.80 | $95,000.00 |
DisclosureSEC source: 0000805928-21-000115 · wf-form4a_162310109457355.xml · nonDerivative · entry 1 NEELS GUIDO J · CIK 0001222362 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,591 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This Form 4 amendment is being filed to correct the original Form 4 filed on May 21, 2021. The original Form 4 had the incorrect address for the reporting person. F2 · shares: The Reporting Person has elected to exercise and hold the shares at this time. Read SEC document |
| April 01, 2021 Filed Apr 5, 2021 20:31 UTC | Bioventus Inc. BVS · Entity 4996 | GrantRestricted Stock Units · Derivative | 2,700 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-014830 · doc4.xml · derivative · entry 1 NEELS GUIDO J · CIK 0001222362 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,700 Underlying: Class A Common Stock · 2,700 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Class A common stock. F2 · derivative.exercise_date: The restricted stock units vest on April 1, 2022 and have no expiration date. F2 · derivative.expiration_date: The restricted stock units vest on April 1, 2022 and have no expiration date. Read SEC document |
| February 11, 2021 Filed Feb 16, 2021 23:13 UTC | Bioventus Inc. BVS · Entity 4996 | GrantRestricted Stock Units · Derivative | 9,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-006749 · doc4.xml · derivative · entry 1 NEELS GUIDO J · CIK 0001222362 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Class A Common Stock · 9,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Class A common stock. F2 · derivative.exercise_date: The restricted stock units vest on February 11, 2022. F2 · derivative.expiration_date: The restricted stock units vest on February 11, 2022. Read SEC document |
| September 03, 2020 Filed Sep 8, 2020 21:37 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantCommon Stock | 2,591 | $11.75 | $30,444.25 |
DisclosureSEC source: 0001179110-20-009636 · edgar.xml · nonDerivative · entry 1 NEELS GUIDO J · CIK 0001222362 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,591 F1 · shares: This reflects the number of restricted stock units that became vested as of September 3, 2020. Read SEC document |
| June 01, 2020 Filed Jun 3, 2020 21:46 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantRestricted Stock Units · Derivative | 4,115 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-006938 · edgar.xml · derivative · entry 2 NEELS GUIDO J · CIK 0001222362 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,115 Underlying: Common Stock · 4,115 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F1 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 2, 2021, one year from the anniversary of the grant date. Two-thirds of the annual equity grant value is in the form of non-qualified stock options and one-third of the annual equity grant value is in the form of restricted stock units. F1 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 2, 2021, one year from the anniversary of the grant date. Two-thirds of the annual equity grant value is in the form of non-qualified stock options and one-third of the annual equity grant value is in the form of restricted stock units. Read SEC document |
| June 01, 2020 Filed Jun 3, 2020 21:46 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantStock Option (right to purchase) · Derivative | 16,807 | $0.00 Strike: $9.72 | $0.00 |
DisclosureSEC source: 0001179110-20-006938 · edgar.xml · derivative · entry 1 NEELS GUIDO J · CIK 0001222362 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,807 Underlying: Common Stock · 16,807 shares Expires 2030-06-01 F1 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 2, 2021, one year from the anniversary of the grant date. Two-thirds of the annual equity grant value is in the form of non-qualified stock options and one-third of the annual equity grant value is in the form of restricted stock units. Read SEC document |
| June 01, 2020 Filed Jun 12, 2020 20:23 UTC Amendment | Axogen, Inc. AXGN · Entity 4297 | GrantRestricted Stock Units · Derivative | 6,173 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-007284 · edgar.xml · derivative · entry 2 NEELS GUIDO J · CIK 0001222362 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,173 Underlying: Common Stock · 6,173 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F3 · shares: The original Form 4, filed June 3, 2020, incorrectly stated the number of derivative securities (Column 5), the number of shares (Column 7) and number of derivatives securities beneficially owned following reported transaction (Column 9) for both the Stock Options and Restricted Stock Units. Footnote 1 has also been amended to reflect the accurate number of stock options and restricted stock units. F1 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 2, 2021, one year from the anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units. F1 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 2, 2021, one year from the anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units. F3 · derivative.underlying_shares: The original Form 4, filed June 3, 2020, incorrectly stated the number of derivative securities (Column 5), the number of shares (Column 7) and number of derivatives securities beneficially owned following reported transaction (Column 9) for both the Stock Options and Restricted Stock Units. Footnote 1 has also been amended to reflect the accurate number of stock options and restricted stock units. F3 · balance_after: The original Form 4, filed June 3, 2020, incorrectly stated the number of derivative securities (Column 5), the number of shares (Column 7) and number of derivatives securities beneficially owned following reported transaction (Column 9) for both the Stock Options and Restricted Stock Units. Footnote 1 has also been amended to reflect the accurate number of stock options and restricted stock units. Read SEC document |
| June 01, 2020 Filed Jun 12, 2020 20:23 UTC Amendment | Axogen, Inc. AXGN · Entity 4297 | GrantStock Option (right to purchase) · Derivative | 12,605 | $0.00 Strike: $9.72 | $0.00 |
DisclosureSEC source: 0001179110-20-007284 · edgar.xml · derivative · entry 1 NEELS GUIDO J · CIK 0001222362 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,605 Underlying: Common Stock · 12,605 shares Expires 2030-06-01 F3 · shares: The original Form 4, filed June 3, 2020, incorrectly stated the number of derivative securities (Column 5), the number of shares (Column 7) and number of derivatives securities beneficially owned following reported transaction (Column 9) for both the Stock Options and Restricted Stock Units. Footnote 1 has also been amended to reflect the accurate number of stock options and restricted stock units. F1 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 2, 2021, one year from the anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units. F3 · derivative.underlying_shares: The original Form 4, filed June 3, 2020, incorrectly stated the number of derivative securities (Column 5), the number of shares (Column 7) and number of derivatives securities beneficially owned following reported transaction (Column 9) for both the Stock Options and Restricted Stock Units. Footnote 1 has also been amended to reflect the accurate number of stock options and restricted stock units. F3 · balance_after: The original Form 4, filed June 3, 2020, incorrectly stated the number of derivative securities (Column 5), the number of shares (Column 7) and number of derivatives securities beneficially owned following reported transaction (Column 9) for both the Stock Options and Restricted Stock Units. Footnote 1 has also been amended to reflect the accurate number of stock options and restricted stock units. Read SEC document |
| September 03, 2019 Filed Sep 5, 2019 21:09 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantRestricted Stock Units · Derivative | 2,591 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-010125 · edgar.xml · derivative · entry 2 NEELS GUIDO J · CIK 0001222362 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,591 Underlying: Common Stock · 2,591 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F1 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on September 3, 2019, one year from the anniversary of the grant date. Two-thirds of the annual equity grant value is in the form of non-qualified stock options and one-third of the annual equity grant value is in the form of restricted stock units. F1 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on September 3, 2019, one year from the anniversary of the grant date. Two-thirds of the annual equity grant value is in the form of non-qualified stock options and one-third of the annual equity grant value is in the form of restricted stock units. Read SEC document |
| September 03, 2019 Filed Sep 5, 2019 21:09 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantStock Option (right to purchase) · Derivative | 10,710 | $0.00 Strike: $15.44 | $0.00 |
DisclosureSEC source: 0001179110-19-010125 · edgar.xml · derivative · entry 1 NEELS GUIDO J · CIK 0001222362 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,710 Underlying: Common Stock · 10,710 shares Expires 2029-09-03 F1 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on September 3, 2019, one year from the anniversary of the grant date. Two-thirds of the annual equity grant value is in the form of non-qualified stock options and one-third of the annual equity grant value is in the form of restricted stock units. Read SEC document |
| April 03, 2019 Filed Apr 3, 2019 16:09 UTC | ENDOLOGIX INC /DE/ ELGX · Entity 146591 | PurchaseCommon Stock | 22,692 | $6.61 | $149,994.12 |
DisclosureSEC source: 0001013606-19-000072 · wf-form4_155432214047185.xml · nonDerivative · entry 1 NEELS GUIDO J · CIK 0001222362 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,200 Read SEC document |
| December 30, 2018 Filed Jan 3, 2019 17:49 UTC | ENDOLOGIX INC /DE/ ELGX · Entity 146591 | GrantCommon Stock | 120,887 | $0.00 | $0.00 |
DisclosureSEC source: 0001013606-19-000024 · wf-form4_154655574279125.xml · nonDerivative · entry 1 NEELS GUIDO J · CIK 0001222362 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 205,089 F1 · kind: 100% of the time-based restricted stock unit award shall vest on December 30, 2019 and shall settle in shares of common stock. Read SEC document |
| June 01, 2018 Filed Jun 5, 2018 21:01 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantStock Option (right to purchase) · Derivative | 4,780 | $0.00 Strike: $49.65 | $0.00 |
DisclosureSEC source: 0001179110-18-008096 · edgar.xml · derivative · entry 1 NEELS GUIDO J · CIK 0001222362 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,780 Underlying: Common Stock · 4,780 shares Expires 2028-06-01 F1 · derivative.exercise_date: Non-qualified stock option grant for service as Director on Company's Board of directors. Options vest in equal installments every three months for the first nine months, with the final installment vesting on the earlier of the date of the 2019 annual shareholders meeting or May 31, 2019. Number of shares pursuant to option are based on $120,000 valuation as of the grant date. Read SEC document |
| February 28, 2018 Filed Mar 1, 2018 15:17 UTC | ENTELLUS MEDICAL INC ENTL · Entity 16119 | Disposition to issuerStock Option (right to buy) · Derivative | 5,000 | $10.62 Strike: $13.38 | $53,100.00 |
DisclosureSEC source: 0001235802-18-000027 · primary_doc.xml · derivative · entry 4 NEELS GUIDO J · CIK 0001222362 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2027-06-13 F4 · derivative.exercise_date: This option, which provided for vesting in full on the earlier of June 13, 2018 and the date of the annual stockholder meeting following June 13, 2017, was canceled in the merger in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $24.00 over the per share exercise price of such option. Read SEC document |
| February 28, 2018 Filed Mar 1, 2018 15:17 UTC | ENTELLUS MEDICAL INC ENTL · Entity 16119 | Disposition to issuerStock Option (right to buy) · Derivative | 10,000 | $5.74 Strike: $18.26 | $57,400.00 |
DisclosureSEC source: 0001235802-18-000027 · primary_doc.xml · derivative · entry 3 NEELS GUIDO J · CIK 0001222362 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2026-06-14 F3 · derivative.exercise_date: This option, which provided for vesting in full on the earlier of June 14, 2017 and the date of the annual stockholder meeting following June 14, 2016, was canceled in the merger in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $24.00 over the per share exercise price of such option. Read SEC document |
| February 28, 2018 Filed Mar 1, 2018 15:17 UTC | ENTELLUS MEDICAL INC ENTL · Entity 16119 | Disposition to issuerStock Option (right to buy) · Derivative | 15,000 | $12.64 Strike: $11.36 | $189,600.00 |
DisclosureSEC source: 0001235802-18-000027 · primary_doc.xml · derivative · entry 2 NEELS GUIDO J · CIK 0001222362 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2024-12-16 F2 · derivative.exercise_date: This option, which provided for vesting in quarterly installments over 36 months commencing on December 1, 2014, was canceled in the merger in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $24.00 over the per share exercise price of such option. Read SEC document |
| February 28, 2018 Filed Mar 1, 2018 15:17 UTC | ENTELLUS MEDICAL INC ENTL · Entity 16119 | Disposition to issuerCommon Stock, $0.001 par value | 17,500 | $24.00 | $420,000.00 |
DisclosureSEC source: 0001235802-18-000027 · primary_doc.xml · nonDerivative · entry 1 NEELS GUIDO J · CIK 0001222362 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Disposed of pursuant to an Agreement and Plan of Merger, dated December 7, 2017, between Entellus Medical, Inc., Stryker Corporation and Explorer Merger Sub Corp. in exchange for a cash payment of $24.00 per share. Read SEC document |
| November 20, 2017 Filed Nov 21, 2017 20:31 UTC | Axogen, Inc. AXGN · Entity 4297 | SaleCommon Stock | 1,150,000 | $19.74 | $22,701,000.00 |
DisclosureSEC source: 0000899243-17-027155 · doc4.xml · nonDerivative · entry 1 NEELS GUIDO J · CIK 0001222362 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Essex Woodlands Fund IX, L.P. Disclosed balance after: 3,371,111 F1 · balance_after: The reported shares are owned directly by Essex Woodlands Fund IX, L.P., a limited partnership of which Essex Woodlands Fund IX-GP, L.P., is the general partner, and of which Essex Woodlands Fund IX, LLC is the general partner. The reporting person is an owner of a limited partnership interest in Essex Woodlands Fund IX, LLC. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. Read SEC document |
| June 13, 2017 Filed Jun 14, 2017 17:00 UTC | ENTELLUS MEDICAL INC ENTL · Entity 16119 | GrantStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $13.38 | $0.00 |
DisclosureSEC source: 0001235802-17-000084 · primary_doc.xml · derivative · entry 2 NEELS GUIDO J · CIK 0001222362 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2027-06-13 F2 · derivative.exercise_date: This option vests in full on the earlier to occur of June 13, 2018 and the date of the Company's annual meeting of stockholders immediately following June 13, 2017, subject to the Reporting Person's continued service with the Company through the applicable vesting date. Read SEC document |
| June 13, 2017 Filed Jun 14, 2017 17:00 UTC | ENTELLUS MEDICAL INC ENTL · Entity 16119 | GrantCommon Stock, $0.001 par value | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001235802-17-000084 · primary_doc.xml · nonDerivative · entry 1 NEELS GUIDO J · CIK 0001222362 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,500 F1 · shares: Includes 2,500 shares that will be issued over time upon vesting pursuant to a restricted stock unit granted under the Entellus Medical, Inc. 2015 Incentive Award Plan. F1 · balance_after: Includes 2,500 shares that will be issued over time upon vesting pursuant to a restricted stock unit granted under the Entellus Medical, Inc. 2015 Incentive Award Plan. Read SEC document |
| June 01, 2017 Filed Jun 8, 2017 17:39 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantStock Option (right to purchase) · Derivative | 15,000 | $0.00 Strike: $14.85 | $0.00 |
DisclosureSEC source: 0001179110-17-008753 · edgar.xml · derivative · entry 1 NEELS GUIDO J · CIK 0001222362 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-06-01 F1 · derivative.exercise_date: Non-qualified stock option grant for service as Director on Company's Board of directors. Options vest in equal installments every three months for the first nine months, with the final installment vesting on the date of the then current annual meeting. Read SEC document |
| May 31, 2017 Filed Jun 2, 2017 12:21 UTC | ENDOLOGIX INC /DE/ ELGX · Entity 146591 | GrantCommon Stock | 22,822 | $0.00 | $0.00 |
DisclosureSEC source: 0001013606-17-000080 · wf-form4_149642044737275.xml · nonDerivative · entry 1 NEELS GUIDO J · CIK 0001222362 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,202 Read SEC document |
| May 19, 2017 Filed May 23, 2017 10:56 UTC | ENDOLOGIX INC /DE/ ELGX · Entity 146591 | PurchaseCommon Stock | 20,000 | $4.32 | $86,400.00 |
DisclosureSEC source: 0001013606-17-000055 · wf-form4_149555135189697.xml · nonDerivative · entry 1 NEELS GUIDO J · CIK 0001222362 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,380 Read SEC document |
| December 29, 2016 Filed Jan 3, 2017 22:06 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantStock Option (right to purchase) · Derivative | 5,000 | $0.00 Strike: $8.95 | $0.00 |
DisclosureSEC source: 0001179110-17-000096 · edgar.xml · derivative · entry 1 NEELS GUIDO J · CIK 0001222362 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2026-12-29 F1 · derivative.exercise_date: Non-qualified stock option grant for service as Director on Company's Board of directors. Vesting is 100% upon the director's re-election to the Company's Board of Directors at the 2017 Annual Meeting of Shareholders. Read SEC document |
| November 18, 2016 Filed Nov 22, 2016 10:27 UTC | ENDOLOGIX INC /DE/ ELGX · Entity 146591 | PurchaseCommon Stock | 13,000 | $7.69 | $99,970.00 |
DisclosureSEC source: 0001013606-16-000321 · wf-form4_147982841828705.xml · nonDerivative · entry 1 NEELS GUIDO J · CIK 0001222362 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,380 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.